Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Punt, C. J. A.
Right arrow Articles by Eggermont, A. M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Punt, C. J. A.
Right arrow Articles by Eggermont, A. M. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:1663-1666, 2001
© 2001 European Society for Medical Oncology

review-article

Adjuvant interferon-alpha for melanoma revisited: News from old and new studies

C. J. A. Punt1, and A. M. M. Eggermont2

1University Medical Center St Radboud Nijmegen The Netherlands
2Erasmus University Medical Center, Daniel den Hoed Cancer Center Rotterdam The Netherlands

C J. A Punt, MD, PhD, Department of Medical Oncology, University Medical Center St. Radboud, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands, E-mail: c.punt{at}onco.azn.nl

Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFN{alpha}) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these trials concern the dose of IFN{alpha}, the duration of IFN{alpha} administration, and the stage of disease. Some of these trials have not yet reached maturity, but despite this the positive results from some immature trials have attracted considerable attention. When only data from mature trials is considered, one may conclude that the use of highdose IFN{alpha} does prolong disease-free survival (DFS) but not overall survival (OS). Combined data from low-dose IFN{alpha} trials does not suggest a benefit in either DFS or OS. A trial with intermediate-dose IFN{alpha} is still immature. Therefore currently the routine use of IFN{alpha} cannot be recommended outside the scope of clinical trials.

adjuvant therapy, interferon-alfa, melanoma, review low-dose IFN{alpha} trials


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
K. I. Amiri, L. W. Horton, B. J. LaFleur, J. A. Sosman, and A. Richmond
Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition: Implication for Bortezomib (VELCADE, PS-341) as a Therapeutic Agent for Malignant Melanoma
Cancer Res., July 15, 2004; 64(14): 4912 - 4918.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. M. Jost
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma
Ann. Onc., July 1, 2003; 14(7): 1012 - 1013.
[Full Text] [PDF]

Home page
 Ann OncolHome page
R. F. Kefford
Adjuvant therapy of cutaneous melanoma: the interferon debate
Ann. Onc., March 1, 2003; 14(3): 358 - 365.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Wheatley and N. Ives
Adjuvant interferon for melanoma
Ann. Onc., August 1, 2002; 13(8): 1319 - 1320.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.